

# ETHICS AND BUSINESS INTEGRITY COMMITTEE (EBIC) CHARTER

## Key objectives / outcomes

EBIC is comprised of representatives from member companies to ensure:

- Ethical promotion of medicines to the HCP's; provide information about products to ensure maximum benefit to the patients and prevent any undue harm to the patients.
- To align with international pharmaceutical bodies to review and update the SAPI code.
- To work with the government bodies, hospitals, medical institutes/associations to ensure alignment and implementation of the SAPI code requirements.
- To review and resolve complaints between member companies related to breach of SAPI code
- To be the advisory body for enquiries/discrepancies with regards to the interpretation of SAPI code

## Meeting Practices and Committee Rules

- Committee member companies may be competitors, creating the risk of anti-competitive conduct. The Committee will adopt the SAPI Competition Guidelines Governing Meetings in full as the rules by which the committee and its members will comply.
- The rules are designed to ensure that in organizing and attending meetings at which competing companies are present, the members avoid engaging in and facilitating any discussion or activity which might violate the competition laws of Singapore.
- The Committee Chair will remind participants of the Competition Guidelines on an annual basis, and with new members of the committee at the point of joining.
- A written agenda will be circulated in advance of each Committee meeting
- Discussion at the meeting should not generally deviate beyond the scope of the agenda
- Written minutes will be taken at the meeting and circulated to all participants after the meeting. The written minutes will also be stored by SAPI in line with its retention policy.
- Where there is doubt as to the legitimacy of a discussion, the Committee Chair, SAPI Secretariat and/ or any member participant must immediately stop the discussion and consider whether such discussion can be continued after SAPI has the opportunity to engage legal counsel to advise the legitimacy of such discussions.

## Prohibited Conduct

It is unlawful to enter into agreements, whether binding or not, that significantly restrict competition in a market. In order to prevent agreements that lessen competition from occurring at meetings, members shall refrain from exchanging competitive information such as:

- Pricing strategies, product pricing, discounts, and credit terms
- Costs of production and distribution, output, methods of computing costs
- Specific suppliers and customers, including any discussion that may have the effect of excluding suppliers or customers from the market
- Confidential future plans of investment, marketing, and technological developments.